The FDA’s action date for Gilead’s bictegravir/lenacapavir combination lands Thursday, August 27, 2026. The company said in an April 2026 release that the FDA granted priority review of the application and assigned that PDUFA date. If approved, the once-daily single-tablet regimen would be the smallest HIV single-tablet option available and the first studied specifically in virologically suppressed adults switching from complex multi-tablet regimens. Gilead’s HIV franchise is already one of the most profitable in the industry. This approval would extend it further. But the more interesting question for long-term investors is whether extending it through one molecule constitutes strength or concentration risk.
Biktarvy generated $14.334 billion in revenue in full-year 2025, up 7% from 2024, and Gilead has said it holds more than 52% of the U.S. HIV treatment market. It is among the largest single products in pharmaceuticals by sales, and Gilead’s HIV segment overall reached $20.8 billion last year. The franchise is exceptional by any financial standard.
Lenacapavir, Gilead’s first-in-class capsid inhibitor, now anchors almost every next-chapter story the company tells. It is already approved as Sunlenca for heavily treatment-experienced adults with multidrug-resistant HIV and as Yeztugo for twice-yearly PrEP prevention. The new BIC/LEN combination pairs bictegravir’s high barrier to resistance with lenacapavir’s novel mechanism, which has no cross-resistance with other antiretrovirals. If approved Thursday, a single capsid inhibitor will span Gilead’s prevention franchise, its treatment upgrade path, and its long-acting pipeline simultaneously.
That is a remarkable scientific achievement. It is also a concentration question that Howard Marks would ask before anyone else in the room: what happens to the terminal value if that one molecule encounters a problem?
The competitive landscape offers partial reassurance and partial warning. In its 2025 annual report, Gilead said it settled Biktarvy patent litigation with generic manufacturers, with no U.S. generic entry expected prior to April 1, 2036 under the agreements. That buys time. But Merck is advancing its own HIV pipeline, including a doravirine/islatravir combination and an investigational once-monthly oral PrEP candidate. Gilead and Merck have also collaborated to evaluate islatravir combined with lenacapavir, a sign that even Gilead’s most important molecule may benefit from a partner’s chemistry to defend its position fully.
The payer environment adds texture. Florida’s AIDS Drug Assistance Program removed Biktarvy from its formulary effective March 1, 2026 for some program channels and later announced that Biktarvy would be restored to the ADAP formulary on July 1, 2026 for enrolled patients. One state program is not a national trend, but it is the kind of official action that tests whether pricing power holds when budgets tighten. Gilead’s pricing has already faced downward pressure even as volume grows.
Thursday’s approval, widely expected by the market, is not the risk event. The risk is the decade-long question of whether one molecule, however well-designed, can carry a franchise worth roughly half of total company revenue. A favorable PDUFA outcome is not the same as a durable answer to that question. Investors who own Gilead as a defensive compounder should recognize they are also holding a concentrated bet on the continued commercial and scientific supremacy of a single drug class. That bet has paid well. It deserves ongoing scrutiny, not just celebration.
